Cardiac Resynchronization in Patients with Mild Heart Failure: Equal Benefit for All?

In an extended follow-up of MADIT- CRT patients, CRT reduced mortality in patients with left bundle-branch block, but not in those without it.

Cardiac resynchronization therapy (CRT) has been demonstrated to improve quality-of-life measures, heart failure (HF) admissions, and left ventricular ejection fraction (LVEF). However, most trials have not had sufficient power or follow-up duration to examine effects on mortality. In the MADIT-CRT trial, CRT reduced rates of a composite endpoint of HF events and death at about 2 years of follow-up. The MADIT-CRT investigators now report longer-term follow-up results.

Post-trial follow-up continued for a median 5.6 years in 1691 patients; a smaller group of 854 was followed longer. At 7 years, rates of death from any cause in patients with left bundle-branch block (LBBB) were 18% in recipients of CRT and 29% in those treated with standard im…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Cardiac Resynchronization in Patients with Mild Heart Failure: Equal Benefit for All?

Topics

Reviewing Author